摘要
OBJECTIVE:To explore the core herbs of two illustrious senior Traditional Chinese Medicine(TCM)Physicians for the treatment of liver cancer,and to further clarify the gene targets and pathway mechanisms of liver cancer that the core prescription(CP)may regulate.METHODS:We used the patient information of two illustrious senior TCM physicians from the Affiliated Hospital of Shandong University of Traditional Chinese Medicine and the Affiliated Hospital of Capital Medical University as the database.The CP was analyzed using the community network algorithm.The pathway mechanism was analyzed using network pharmacology method.And the prognostic survival genes were identified using Single factor cox regression analysis.Integrative Pharmacology-based Research Platform of Traditional Chinese Medicine(TCMIP),Herb,Online Mendelian Inheritance in Man(OMIM),Genecards,Kyoto Encyclopedia of Genes and Genomes(KEGG),Genomic Data Commons(GDC),The Cancer Genome Atlas(TCGA),Gephi and R were used to mine CP,building a pathway network diagram.All the analyses were visualized.RESULTS:We found that the CP consistes of Huangqi(Radix Astragali Mongolici),Danshen(Radix Salviae Miltiorrhizae),Shuihonghuazi(Polygoni Orientalis Fructus),Baihuasheshecao(Herba Hedyotdis),Banzhilian(Herba Scutellariae Barbatae),and Ezhu(Rhizoma Curcumae Phaeocaulis),which were attributed to the two physicians respectively.The CP played an anticancer role through such pathways as signal transduction,energy metabolism,immune system and other pathways,covering a total of 112 pathways and 176 herb-diseaserelated genes.Fourteen genes have a significant impact on the prognosis and survival of liver cancer.CONCLUSION:Based on the liver cancer cases of two illustrious senior TCM physicians,we obtained the CP through data mining.The CP may mainly exert anticancer effects by inhibiting inflammatory response,angiogenesis,and enhancing the body’s immune response.We screened out 14 genes in the CP that may be related to the prognosis of liver cancer,and these genes may pla
基金
Supported by National Key R&D Program of China(Research on Inheritance and Innovation of Experience(Integration of Tao and Shu)of Illustrious Senior Traditional Chinese Medicine Practitioners by adopting Multiple Research Methods 2018YFC1704100 and Research on Methodology System and Paradigms for Mining and Inheriting Illustrious Senior Traditional Chinese Medicine Practitioners’Experience 2018YFC1704101)。
